Adaptive Biotechnologies Corporation — Company profile
Healthcare · Biotechnology · United States
Last price 26.64 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 4.25B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Details
| Name | Adaptive Biotechnologies Corporation |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Employees | 624 |
| Founded | 2009 |
| Ipo Date | 2019-06-27 |
| Ceo | Chad Robins |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 20.00 |
| Isin | US00650F1093 |
| Cusip | 00650F109 |
| Cik | 1478320 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Chad M. Robins M.B.A. | Co-Founder, Chief Executive Officer and Chairman |
| Julie Rubinstein | President and Chief Operating Officer |
| Kyle Piskel | Vice President, Chief Financial Officer and Principal Accounting Officer |
| Susan Bobulsky | Chief Commercial Officer of MRD |
| Christopher Carlson Ph.D. | Founder |
| Karina Calzadilla | Vice President of Investor Relations and FP&A |
| Clarice McCauley | Head of Legal, Corporate Secretary, Vice President and Chief Compliance Officer |
| Francis T. Lo | Chief People Officer |
| Dr. Sharon Benzeno Ph.D. | Chief Commercial Officer of Immune Medicine |
| Mary Pat Lancelotta | Senior Vice President, Global Market and Business Development |
Contact
| Address | 1165 Eastlake Avenue East, Seattle, Washington 98109, United States |
| Phone | 206 659 0067 |
| Website | https://www.adaptivebiotech.com |